TOP FIVE HIGHLIGHTS

1

IVST is up 2287% YTD

IVST is up 2287% YTD; from $0.023 on zero revenue to 0.5262 on $34 million revenue.

2

Added $34 Million sales

IVST added $34 million sales run rate YTD through growth model of acquisitions.

3

Pending Acquisition to add $12 Million in Revenue

LOI on Pending Acquisition to add $12 Million in revenue. CEO calls it "business as usual".

4

11.8M Shares in the Float

11.8M shares in the Float, unchanged for over two years.

5

No Convertible Debts, Warrants, or Options

IVST has no convertible debts, warrants, or options.

IVST announced a LOI to acquire $12 million revenue generating company Midwest Curtainwalls in the second half of 2018. Announcement Pending!

In addition to an expected 2018 annual revenue run rate of $46 Million (+) in revenue, IVST also launched a biotech division which owns a stake in the brain cancer vaccine, StemVax Glioblast (SVX-GB), including the patent number #US9764014B2 with it's investment in StemVax Therapeutics which was recently featured in the LA Business Journal in August.

IVST is a rare high growth opportunity, with rapidly growing revenue, valuable intellectual property, VERY few shares available, and ZERO debt.
Management has disclosed plans to list IVST on the Nasdaq or NYSE as soon as possible, based on it's current trajectory which includes stock price increases of 2287% Year To Date.
To visit the IVST website, click here.